2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be v...

Full description

Saved in:

Bibliographic Details
Published in:	Arthritis care & research (2010) Vol. 63; no. 4; pp. 465 - 482
Main Authors:	Beukelman, Timothy, Patkar, Nivedita M., Saag, Kenneth G., Tolleson‐Rinehart, Sue, Cron, Randy Q., DeWitt, Esi Morgan, Ilowite, Norman T., Kimura, Yukiko, Laxer, Ronald M., Lovell, Daniel J., Martini, Alberto, Rabinovich, C. Egla, Ruperto, Nicolino
Format:	Journal Article
Language:	English
Published:	Hoboken, USA John Wiley & Sons, Inc 01-04-2011
Subjects:	Animals Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Arthritis - diagnosis Arthritis - drug therapy Arthritis, Juvenile - diagnosis Arthritis, Juvenile - drug therapy Humans Monitoring, Physiologic - standards Practice Guidelines as Topic - standards Rheumatology - methods Rheumatology - standards Societies, Medical - standards Treatment Outcome United States United States
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
Bibliography:	Members of the Core Expert Panel: Timothy Beukelman, MD, MSCE, Randy Q. Cron, MD, PhD, Esi Morgan DeWitt, MD, MSCE, Norman T. Ilowite, MD, Yukiko Kimura, MD, Ronald M. Laxer, MDCM, FRCPC, Daniel J. Lovell, MD, MPH, Alberto Martini, MD, C. Egla Rabinovich, MD, MPH, Nicolino Ruperto, MD, MPH. Members of the Task Force Panel: Suzanne L. Bowyer, MD (Indiana University School of Medicine, Indianapolis), Pavla Dolezalova, MD, PhD (Charles University, Prague, Czech Republic), Ciaran M. Duffy, MBBCh, MSc (McGill University, Montreal, Quebec, Canada), James P. Guevara, MD, MPH (Children's Hospital of Philadelphia, Philadelphia, PA), Anne Murphy, PhD (University of California, San Diego), Murray H. Passo, MD (Medical University of South Carolina, Charleston), Marilynn Punaro, MD (University of Texas Southwestern, Dallas), Rayfel Schneider, MBBCh, FRCPC (University of Toronto and Hospital for Sick Children, Toronto, Ontario, Canada), David D. Sherry, MD (Children's Hospital of Philadelphia, Philadelphia, PA), Earl D. Silverman, MD, FRCPC (University of Toronto and Hospital for Sick Children, Toronto, Ontario, Canada), Janalee Taylor, RN, MSN, CPNP (Cincinnati Children's Hospital Medical Center, Cincinnati, OH), Carol A. Wallace, MD (Seattle Children's Hospital Medical Center, Seattle, WA). The American College of Rheumatology is an independent professional, medical, and scientific society which does not guarantee, warrant, or endorse any commercial product or service. Dr. Ilowite has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Genentech. Dr. Ruperto has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Bristol‐Myers Squibb, Roche, and Novartis. Members of the University of Alabama at Birmingham Working Group: Sheree Carter, RN, MSN, Jeffrey R. Curtis, MD, MPH, Archana Jain, MD, Amy Mudano, MPH, Pongthorn Narongroeknawin, MD. Dr. Kimura has served on the advisory board for Genentech and received a fee (less than $10,000). Dr. Martini has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Bristol‐Myers Squibb. American College of Rheumatology Board of Directors Liaison: Raphael Hirsch, MD (University of Pittsburgh, Pittsburgh, PA). Dr. Laxer is the Chair of the advisory board for Novartis and receives a fee (less than $10,000). Dr. Saag has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Merck, Lilly, Novartis, P&G, Aventis, Genentech, Takeda, AstraZeneca, and Horizon. Members of the University of North Carolina at Chapel Hill Working Group: Rachel Fesperman, MD, MPH, Bethany Koestner, MSLS, Lynne Morris, MLS, Karen Rusak, MD, MPH.
ISSN:	2151-464X 2151-4658
DOI:	10.1002/acr.20460